SEARCH:   Advanced

Blood, 15 February 2004, Vol. 103, No. 4, pp. 1222-1228. Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-04-1124. This Article Full Text (PDF) All Versions of this Article: 2003-04-1124v1 103/4/1222    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Andre, M. P Articles by Gisselbrecht, C. Search for Related Content PubMed PubMed Citation Articles by Andre, M. P Articles by Gisselbrecht, C. Social Bookmarking                   What's this? Submitted April 11, 2003 Accepted July 30, 2003 Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen. A GELA cohort study on 2837 patients Marc P Andre*, Nicolas Mounier, Xavier Leleu, Anne Sonet, Pauline Brice, Michel Henry-Amar, Herve Tilly, Bertrand Coiffier, Andre Bosly, Pierre Morel, Corinne Haioun, Philippe Gaulard, Felix Reyes, and Christian Gisselbrecht Department of Hematology, Centre Hospitalier Notre Dame et reine Fabiola, Charleroi, Belgium Department of Hematology, Hopital Saint-Louis, Paris, France Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France Department of Hematology, Cliniques Universitaires Mont Godinne, Yvoir, Belgium Clinical Research Unit and INSERM CJF 96-03/GRECAN, Centre Regional Francois Baclesse, Caen, France Department of Hematology, Centre Henri Becquerel, Rouen, France Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France Department of Hematology, Centre Hospitalier de Lens, Lens, France Department of Hematology and Pathology, Hopital Henri Mondor, Paris, France * Corresponding author; email: andre.marc{at}chndrf.be. The survival of aggressive NHL is increasing, but the incidence of secondary cancer and late toxicities is poorly defined for these patient treated with CHOP-like chemotherapy. From 02/1984 to 01/1998, 2837 patients with aggressive NHL received the control arm chemotherapy ACVBP in three consecutive GELA studies. With a median follow-up of 74 months, the 5 years overall and event-free survival were 60% and 52%. 202 non-neoplasic late toxicities were reported and this resulted in a 5.35% cumulative probability of incidence at 7 years. 81 second tumors were observed and the 7-years cumulative incidence rate was 2.75%. There were 64 solid tumors and 17 hematologic malignancies. In multivariate analysis, age was the only risk factor for the development of second cancer. An epidemiological analysis allowed a comparison of this NHL group with the general population. Considering all tumors, no excess of second cancer was observed. But in the male population, there was an excess of lung cancer (SIR:2.45, p<0.001) and MDS/AML (SIR:5.65,p=0.006) and in the female population there was an excess of MDS/AML (SIR:19.9,p<0.001). With a long follow-up, ACVB regimen is highly effective for the treatment of aggressive NHL. An increase of secondary MDS/AML and male lung cancer was observed. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Green, M. Johnston, M. Trudeau, L. Schwartz, S. Poirier, G. Macartney, and D. Milliken Safe Handling of Parenteral Cytotoxics: Recommendations for Ontario J. Oncol. Pract, September 1, 2009; 5(5): 245 - 249. [Abstract] [Full Text] [PDF] X. Leleu, J. Soumerai, A. Roccaro, E. Hatjiharissi, Z. R. Hunter, R. Manning, B. T. Ciccarelli, A. Sacco, L. Ioakimidis, S. Adamia, et al. Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom Macroglobulinemia Treated With Nucleoside Analogs J. Clin. Oncol., January 10, 2009; 27(2): 250 - 255. [Abstract] [Full Text] [PDF] S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, P. G. Gobbi, F. Angrilli, M. Brugiatelli, P. Musto, and M. Federico Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study Haematologica, September 1, 2008; 93(9): 1335 - 1342. [Abstract] [Full Text] [PDF] S. Sacchi Reply to: [Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403 Haematologica, July 1, 2008; 93(7): e58 - e58. [Full Text] [PDF] E. C. Bluhm, C. Ronckers, R. J. Hayashi, J. P. Neglia, A. C. Mertens, M. Stovall, A. T. Meadows, P. A. Mitby, J. A. Whitton, S. Hammond, et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study Blood, April 15, 2008; 111(8): 4014 - 4021. [Abstract] [Full Text] [PDF] S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, S. Luminari, M. Lombardo, G. Buda, A. Lazzaro, P. G. Gobbi, et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study Haematologica, March 1, 2008; 93(3): 398 - 404. [Abstract] [Full Text] [PDF] G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso Therapy-related leukemia and myelodysplasia: susceptibility and incidence Haematologica, October 1, 2007; 92(10): 1389 - 1398. [Abstract] [Full Text] [PDF] M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon, S. Revell, K. Vo, and A. Molina Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy J. Clin. Oncol., September 20, 2007; 25(27): 4285 - 4292. [Abstract] [Full Text] [PDF] G Sanna, K Lorizzo, N Rotmensz, V Bagnardi, S Cinieri, M Colleoni, F Nole, and A Goldhirsch Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors Ann. Onc., February 1, 2007; 18(2): 288 - 292. [Abstract] [Full Text] [PDF] N. Y. Mudie, A. J. Swerdlow, C. D. Higgins, P. Smith, Z. Qiao, B. W. Hancock, P. J. Hoskin, and D. C. Linch Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study J. Clin. Oncol., April 1, 2006; 24(10): 1568 - 1574. [Abstract] [Full Text] [PDF] E. C. Moser, E. M. Noordijk, F. E. van Leeuwen, S. le Cessie, J. W. Baars, J. Thomas, P. Carde, J. H. Meerwaldt, M. van Glabbeke, and H. C. Kluin-Nelemans Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma Blood, April 1, 2006; 107(7): 2912 - 2919. [Abstract] [Full Text] [PDF] D. P. Steensma and J. M. Bennett The Myelodysplastic Syndromes: Diagnosis and Treatment Mayo Clin. Proc., January 1, 2006; 81(1): 104 - 130. [Abstract] [Full Text] [PDF] H. Sill, W. Olipitz, and M. G. Schimek Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia After Autologous Bone Marrow Transplantation: Dosis Facit Venenum? J. Clin. Oncol., November 1, 2005; 23(31): 8120 - 8121. [Full Text] [PDF] J. R. Brown and A. S. Freedman In Reply: J. Clin. Oncol., November 1, 2005; 23(31): 8121 - 8122. [Full Text] [PDF] P. McLaughlin, E. Estey, A. Glassman, J. Romaguera, F. Samaniego, A. Ayala, K. Hayes, A. M. Maddox, H. A. Preti, and F. B. Hagemeister Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha Blood, June 15, 2005; 105(12): 4573 - 4575. [Abstract] [Full Text] [PDF] T. Tanvetyanon, M. Adli, A. Sevinc, M. E. Kalender, S. Hoecht, W. Hinkelbein, F. Reyes, and H. Tilly Treatment of Localized Lymphoma N. Engl. J. Med., June 9, 2005; 352(23): 2449 - 2451. [Full Text] [PDF] G. Dranitsaris, M. Johnston, S. Poirier, T. Schueller, D. Milliken, E. Green, and B. Zanke Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature Journal of Oncology Pharmacy Practice, June 1, 2005; 11(2): 69 - 78. [Abstract] [PDF] C. S.J. Duchateau and M. P.M. Stokkel Second Primary Tumors Involving Non-small Cell Lung Cancer: Prevalence and Its Influence on Survival Chest, April 1, 2005; 127(4): 1152 - 1158. [Abstract] [Full Text] [PDF] J. R. Brown, H. Yeckes, J. W. Friedberg, D. Neuberg, H. Kim, L. M. Nadler, and A. S. Freedman Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma J. Clin. Oncol., April 1, 2005; 23(10): 2208 - 2214. [Abstract] [Full Text] [PDF] F. Reyes, E. Lepage, G. Ganem, T. J. Molina, P. Brice, B. Coiffier, P. Morel, C. Ferme, A. Bosly, P. Lederlin, et al. ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma N. Engl. J. Med., March 24, 2005; 352(12): 1197 - 1205. [Abstract] [Full Text] [PDF] A. Tichelli and G. Socie Considerations for Adult Cancer Survivors Hematology, January 1, 2005; 2005(1): 516 - 522. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020